3 ASX 200 Healthcare Shares to Buy
These updates show healthcare companies improving through new contracts clinical progress and better performance whereas focusing on growth efficiency and maintaining strong financial stability for future visibility.Β
Pro Medicus Limited (ASX: PME)
Pro Medicus Limited (ASX: PME) on 1 April 2026 announced on market buyback up to ten percent shares until March 2027 showing confidence
On 9 March 2026 signed year renewals worth 40M with Medstar and Zwanger Pesiri increasing transaction pricing and adding cardiology
For period ending December 2025 revenue reached 124.8m profit rose margins improved cash increased company stayed debt free paying dividends
During period multiple contracts announced including July 2025 Colorado deal and others totaling over 280 million strengthening future revenue visibility.
Telix Pharmaceuticals Limited (ASX: TLX)
Telix Pharmaceuticals Limited (ASX: TLX) on 16 March 2026 resubmitted NDA to FDA for Pixclara brain imaging after providing extra data addressing earlier response concerns
The candidate targets recurrent glioma detection in adults and children with orphan and fast track status showing unmet need opportunity
On 10 March 2026, Phase three ProstACT study part one met goals confirming safety tolerability and expected side effects profile
Results showed therapy works with standard treatments and study now moves forward indicating progress toward broader clinical use potential
Ramsay Health Care Limited (ASX: RHC)
Ramsay Health Care Limited (ASX: RHC) on 26 February 2026 reported half year results showing underlying profit rising 8.1 percent mainly from stronger Australian operations and better hospital performance
During the period Australia segment improved margins patient demand increased and hospital capacity expanded while portfolio changes and planned acquisition aim to enhance future growth
Capital management tightened with lower spending guidance new hospital opened under budget and restructuring efforts reduced costs while distribution of Ramsay Sante stake planned
Profit surged due to prior impairments while outlook expects continued Australia momentum weaker UK activity and gradual improvement across Europe with controlled spending and stable dividends.Β
(Source: Company Report)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations β 7βday free trial
Independent, analystβdriven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether itβs appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.